Taking people in SpainPhase 1
Xdivane compared with Opdivo in adults after melanoma surgery
Compares Xdivane with Opdivo in adults whose melanoma was surgically removed.
Key facts
- Who runs it
- Intas Pharmaceuticals Limited
- Where
- Badajoz, Barcelona, Cáceres, Madrid, and Málaga, SpainSee the 6 sitesAlso in 1 other country, 3 sites
- Trial code
- Registry title
- A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 34 people, planned
- Started
- 19 Jan 2026
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional
- Record updated
- 13 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma that has been surgically removed. It compares Xdivane with Opdivo®.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Resected melanoma (melanoma removed by surgery)
Where in Spain
Also in 1 other country, 3 sites
- Hospital Universitario de BadajozBadajoz, SpainTaking people
- Hospital Clinic de BarcelonaBarcelona, SpainTaking people
- Hospital San Pedro De AlcántaraCáceres, SpainTaking people
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
- Hospital Quironsalud MalagaMálaga, SpainTaking people
- Hospital Universitario Regional de MálagaMálaga, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Xdivane compared with Opdivo in adults after melanoma surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 13 February 2026